Osteoprotegerin expression during the micro- and macrometastatic phases of the osteoblastic metastasis in prostate cancer: Therapeutic implications

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 12, 2013, Pages 1395-1403

  Pneumaticos, Spyros G ^a   Christofides, Anthos ^a   Gkioka, Eliona ^a   Kalogeropoulos, Theodoros ^b   Msaouel, Pavlos ^a,c   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Anticancer Oncologic Hospital Saint Savvas   (Greece)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Bone microenvironment; OPG; Osteoblastic metastasis; Osteoclastogenesis; RANK; RANKL

Indexed keywords

ANDROGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

BONE METABOLISM; BONE METASTASIS; CANCER CHEMOTHERAPY; DISEASE COURSE; HUMAN; MEDIATOR RELEASE; MICROMETASTASIS; OSTEOCLASTOGENESIS; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR INVASION;

ANIMALS; BONE NEOPLASMS; HUMANS; MALE; OSTEOBLASTS; OSTEOPROTEGERIN; PROSTATIC NEOPLASMS;

EID: 84887936245     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.834889     Document Type: Review

References (62)

1. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: Potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001;92:460-70
2. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) 2006;110:279-91
3. Khosla S. Minireview: The OPG/ RANKL/RANK system. Endocrinology 2001;142:5050-5
4. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-53
5. Yeung RS. The osteoprotegerin/ osteoprotegerin ligand family: Role in inflammation and bone loss. J Rheumatol 2004;31:844-6
6. Morony S, Capparelli C, Sarosi I, et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-6
7. Koutsilieris M, Frenette G, Lazure C, et al. Urokinase-Type plasminogen activator: A paracrine factor regulating the bioavailability of IGFs in PA-III cellinduced osteoblastic metastases. Anticancer Res 1993;13:481-6
8. Koutsilieris M, Laroche B, Thabet M, et al. The assessment of disease aggressivity in stage D2 prostate cancer patients (review). Anticancer Res 1990;10:333-6
9. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93
10. Reddi AH, Roodman D, Freeman C, et al. Mechanisms of tumor metastasis to the bone: Challenges and opportunities. J Bone Miner Res 2003;18:190-4
11. Msaouel P, Pissimissis N, Halapas A, et al. Mechanisms of bone metastasis in prostate cancer: Clinical implications. Best Pract Res Clin Endocrinol Metab 2008;22:341-55
12. Koutsilieris M, Tolis G. Long-Term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: Classification of variables associated with disease outcome. Prostate 1985;7:31-9
13. Mundy GR. Mechanisms of bone metastasis. Cancer 1997;80:1546-56
14. Koutsilieris M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 1993;13:443-9
15. Koutsilieris M. Skeletal metastases in advanced prostate cancer: Cell biology and therapy. Crit Rev Oncol Hematol 1995;18:51-64
16. Koutsilieris M, Dupont A, Gomez J, et al. Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal treatment (GnRH-A plus flutamide). Anticancer Res 1994;14:627-34
17. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000;88:2892-8
18. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213s-6s
19. Koutsilieris M. Prostate-derived growth factors for bone cells: Implications for bone physiology and pathophysiology: Review. In Vivo 1988;2:377-83
20. Koutsilieris M, Rabbani SA, Bennett HP, et al. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest 1987;80:941-6
21. Koutsilieris M, Rabbani SA, Goltzman D. Selective osteoblast mitogens can be extracted from prostatic tissue. Prostate 1986;9:109-15
22. Koutsilieris M, Rabbani SA, Goltzman D. Effects of human prostatic mitogens on rat bone cells and fibroblasts. J Endocrinol 1987;115:447-54
23. Karamanolakis D, Bogdanos J, Sourla A, et al. Molecular evidence-based use of bone resorption-Targeted therapy in prostate cancer patients at high risk for bone involvement. Mol Med 2002;8:667-75
24. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64
25. Bendre MS, Margulies AG, Walser B, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 2005;65:11001-9
26. Chikazu D, Li X, Kawaguchi H, et al. Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: Role in effects of bone morphogenetic protein 2 in vitro and in vivo. J Bone Miner Res 2002;17:1430-40
27. Sunyer T, Lewis J, Collin-Osdoby P, et al. Estrogens bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J Clin Invest 1999;103:1409-18
28. Koutsilieris M, Polychronakos C. Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. Anticancer Res 1992;12:905-10
29. Tenta R, Sourla A, Lembessis P, et al. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Horm Metab Res 2005;37:593-601
30. Reyes-Moreno C, Sourla A, Choki I, et al. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. Urology 1998;52(2):341-7
31. Bogdanos J, Karamanolakis D, Tenta R, et al. Endocrine/paracrine/ autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer 2003;10:279-89
32. Koutsilieris M, Sourla A, Pelletier G, et al. Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer. J Bone Miner Res 1994;9:1823-32
33. Mitsiades CS, Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin Investig Drugs 2001;10:1099-115
34. Dalezis P, Geromichalos GD, Trafalis DT, et al. Dexamethasone plus octreotide regimen increases anticancer effects of docetaxel on TRAMP-C1 prostate cancer model. In Vivo 2012;26:75-86
35. Koutsilieris M, Dimopoulos T, Milathianakis C, et al. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis. BJU Int 2007;100(Suppl 2):60-2
36. Koutsilieris M, Mitsiades CS, Bogdanos J, et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 2004;10:4398-405
37. Mitsiades CS, Bogdanos J, Karamanolakis D, et al. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res 2006;26:3693-700
38. Tenta R, Tiblalexi D, Sotiriou E, et al. Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. Prostate 2004;59:120-31
39. Toulis KA, Goulis DG, Msaouel P, et al. Dexamethasone plus somatostatin-Analog manipulation as bone metastasis microenvironment-Targeting therapy for the treatment of castration-resistant prostate cancer: A meta-Analysis of uncontrolled studies. Anticancer Res 2012;32:3283-9
40. Ryser MD, Qu Y, Komarova SV. Osteoprotegerin in bone metastases: Mathematical solution to the puzzle. PLoS Comput Biol 2012;8(10):e1002703
41. Holen I, Croucher PI, Hamdy FC, et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002;62(6):1619-23
42. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44
43. Katopodis H, Philippou A, Tenta R, et al. MG-63 osteoblast-like cells enhance the osteoprotegerin expression of PC-3 prostate cancer cells. Anticancer Res 2009;29:4013-18
44. Mountzios G, Dimopoulos MA, Bamias A, et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/ osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 2007;46:221-9
45. Chen G, Sircar K, Aprikian A, et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006;107:289-98
46. Armstrong AP, Miller RE, Jones JC, et al. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 2008;68:92-104
47. Coleman RE. Metastatic bone disease and the role of biochemical markers of bone metabolism in benign and malignant diseases. Cancer Treat Rev 2001;27:133-5
48. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692-6
49. Logothetis CJ. Treatment of prostate cancer metastases: More than semantics. Lancet 2012;379:4-6
50. Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48
51. Koutsilieris M, Mitsiades C, Dimopoulos T, et al. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 2001;86:5729-36
52. Lembessis P, Msaouel P, Halapas A, et al. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clin Chem Lab Med 2007;45:1488-94
53. Mitsiades CS, Lembessis P, Sourla A, et al. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis 2004;21:495-505
54. Panteleakou Z, Lembessis P, Sourla A, et al. Detection of circulating tumor cells in prostate cancer patients: Methodological pitfalls and clinical relevance. Mol Med 2009;15:101-14
55. Sourla A, Lembessis P, Mitsiades C, et al. Conversion of nested reverse-Transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients. Anticancer Res 2001;21:3565-70
56. Lipton A, Balakumaran A. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors. Expert Rev Clin Pharmacol 2012;5:359-71
57. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377(9768):813-22
58. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68
59. Saad F, Gleason DM, Murray R, et al. Long-Term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82
60. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9
61. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273(23):14363-7
62. Falschlehner C, Schaefer U, Walczak H. Following TRAILs path in the immune system. Immunology 2009;127:145-54